These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 21172927)
21. Review on the influence of protocol design on clinical outcomes in rheumatoid arthritis treated with rituximab. Shetty S; Fisher MC; Ahmed AR Ann Pharmacother; 2013 Mar; 47(3):311-23. PubMed ID: 23447479 [TBL] [Abstract][Full Text] [Related]
22. [Recommendations on the use of rituximab for patients with rheumatoid arthritis]. Rubbert-Roth A; Burmester G; Z Rheumatol; 2008 Nov; 67(7):609-13. PubMed ID: 18830700 [No Abstract] [Full Text] [Related]
24. Usefulness of power Doppler ultrasound for prediction of re-therapy with rituximab in rheumatoid arthritis: a prospective study of longstanding rheumatoid arthritis patients. Reiche BE; Ohrndorf S; Feist E; Messerschmidt J; Burmester GR; Backhaus M Arthritis Care Res (Hoboken); 2014 Feb; 66(2):204-16. PubMed ID: 23925935 [TBL] [Abstract][Full Text] [Related]
25. Usefulness of monitoring of B cell depletion in rituximab-treated rheumatoid arthritis patients in order to predict clinical relapse: a prospective observational study. Trouvin AP; Jacquot S; Grigioni S; Curis E; Dedreux I; Roucheux A; Boulard H; Vittecoq O; Le Loët X; Boyer O; Goëb V Clin Exp Immunol; 2015 Apr; 180(1):11-8. PubMed ID: 25370437 [TBL] [Abstract][Full Text] [Related]
26. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate. Rigby W; Ferraccioli G; Greenwald M; Zazueta-Montiel B; Fleischmann R; Wassenberg S; Ogale S; Armstrong G; Jahreis A; Burke L; Mela C; Chen A Arthritis Care Res (Hoboken); 2011 May; 63(5):711-20. PubMed ID: 21557525 [TBL] [Abstract][Full Text] [Related]
27. [Consensus on the Use of Rituximab in Rheumatoid Arthritis. A document with evidence-based recommendations. Grupo de Expertos en Rituximab. ]. Martín Mola E; Hernández B; García-Arias M; Alvaro-Gracia JM; Balsa A; Reino JG; Marenco de la Fuente JL; Martínez-Taboada V; Ivorra JA; Sanmartí R; Reumatol Clin; 2011; 7(1):30-44. PubMed ID: 21794777 [TBL] [Abstract][Full Text] [Related]
28. Update 2011: leflunomide in rheumatoid arthritis - strengths and weaknesses. Behrens F; Koehm M; Burkhardt H Curr Opin Rheumatol; 2011 May; 23(3):282-7. PubMed ID: 21427581 [TBL] [Abstract][Full Text] [Related]
29. [Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy in Poland]. Samborski W; Buczek J; Bednarek A; Lewandowicz J; Kucharz E Pol Merkur Lekarski; 2010 Dec; 29(174):365-8. PubMed ID: 21298986 [TBL] [Abstract][Full Text] [Related]
30. Progression of structural damage is not related to rituximab serum levels in rheumatoid arthritis patients. Boumans M; Teng O; Thurlings R; Bijlsma J; Gerlag D; Huizinga T; Vos K; Stapel S; Wolbink G; Tekstra J; van Laar J; Tak PP Rheumatology (Oxford); 2013 Aug; 52(8):1462-6. PubMed ID: 23620560 [TBL] [Abstract][Full Text] [Related]
31. Eficiency of different doses of rituximab in rheumatoid arthritis. Mena-Vázquez N; Manrique-Arija S; Ureña-Garnica I; Romero-Barco CM; Jiménez-Núñez FG; Coret V; Irigoyen-Oyarzábal MV; Fernández-Nebro A Reumatol Clin; 2016; 12(3):139-45. PubMed ID: 26458761 [TBL] [Abstract][Full Text] [Related]
32. Comment on: Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Belmonte Serrano MA; Pincus T Rheumatology (Oxford); 2010 Sep; 49(9):1795-6; author reply 1796-7. PubMed ID: 20484342 [No Abstract] [Full Text] [Related]
33. Late-onset neutropenia in patients with rheumatoid arthritis after treatment with rituximab. Abdulkader R; Dharmapalaiah C; Rose G; Shand LM; Clunie GP; Watts RA J Rheumatol; 2014 May; 41(5):858-61. PubMed ID: 24634201 [TBL] [Abstract][Full Text] [Related]
34. The updated guidelines on the use of rituximab in rheumatoid arthritis. Lopez-Olivo MA; Tayar JH; Suarez-Almazor ME Rheumatology (Oxford); 2011 Dec; 50(12):2153-4. PubMed ID: 21546350 [No Abstract] [Full Text] [Related]
35. Efficacy of rituximab in patients with rheumatoid arthritis refractory or with contra-indication to anti-tumor necrosis factor-alpha drugs in daily practice: an open label observational study. Assous N; Gossec L; Dougados M; Kahan A; Allanore Y Clin Exp Rheumatol; 2007; 25(3):504. PubMed ID: 17631755 [No Abstract] [Full Text] [Related]
36. The potential risk of infections during (prolonged) rituximab therapy in rheumatoid arthritis. Brinkman IH; van de Laar MA; Jansen TL; van Roon EN Expert Opin Drug Saf; 2011 Sep; 10(5):715-26. PubMed ID: 21401437 [TBL] [Abstract][Full Text] [Related]
37. Tocilizumab: new drug. Rheumatoid arthritis: another 'mab', no therapeutic advantage. Prescrire Int; 2009 Oct; 18(103):198-201. PubMed ID: 19882783 [TBL] [Abstract][Full Text] [Related]
38. Long-term repopulation of peripheral B-cell subsets after single and repeated rituximab infusions in patients with rheumatoid arthritis. Roll P; Mahmood Z; Muhammad K; Feuchtenberger M; Dörner T; Tony HP Clin Exp Rheumatol; 2015; 33(3):347-53. PubMed ID: 25897997 [TBL] [Abstract][Full Text] [Related]
39. [Proposal for biologic drugs therapy in rheumatoid arthritis]. Curković B; Babić-Naglić D; Morović-Vergles J; Anić B; Grazio S; Kaliterna DM; Hanih M; Novak S Reumatizam; 2010; 57(1):29-35. PubMed ID: 20941938 [TBL] [Abstract][Full Text] [Related]
40. New and promising treatments for rheumatoid arthritis. Looney RJ; Stohl W Am J Orthop (Belle Mead NJ); 2007 Jul; 36(7 Suppl):18-23. PubMed ID: 17694190 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]